Codexis, Inc. announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis' Codex® HiCap RNA Polymerase. Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex®? Hi Cap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties.

Codexis and Aldevron will work together to ensure a smooth changeover for customers during a transitional period. Codex® HiCap RNA Polymerase is a uniquely engineered, co-transcriptional capping RNA polymerase that enables researchers to produce synthetic mRNA at the high yield and purity that today?s mRNA-based vaccines and therapeutics demand. It incorporates commercially available cap analogs more efficiently than wild-type T7 (WT T7) RNA polymerase, generates less undesirable double-stranded RNA (dsRNA) byproduct and provides efficient in vitro transcription (IVT).